Listar por autor "Dimopoulos, M. A."
Mostrando ítems 1-7 de 7
-
Association of VEGF-A Splice Variant mRNA Expression With Outcome in Bevacizumab-Treated Patients With Metastatic Breast Cancer
Pentheroudakis, G.; Kotoula, V.; Kouvatseas, G.; Charalambous, E.; Dionysopoulos, D.; Zagouri, F.; Koutras, A.; Papazisis, K.; Pectasides, D.; Samantas, E.; Dimopoulos, M. A.; Papandreou, C. N.; Fountzilas, G. (2014)We studied tissue mRNA levels of VEGF-Axxxa angiogenic versus VEGF-Axxxb anti-angiogenic isoforms by means of specially designed PCR assays in two parallel cohorts of metastatic breast cancer patients, one treated with ... -
Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients
Katodritou, E.; Terpos, E.; Symeonidis, A. S.; Pouli, A.; Kelaidi, C.; Kyrtsonis, M. C.; Kotsopoulou, M.; Delimpasi, S.; Christoforidou, A.; Giannakoulas, N.; Viniou, N. A.; Stefanoudaki, E.; Hadjiaggelidou, C.; Christoulas, D.; Verrou, E.; Gastari, V.; Papadaki, S.; Polychronidou, G.; Papadopoulou, A.; Giannopoulou, E.; Kastritis, E.; Kouraklis, A.; Konstantinidou, P.; Anagnostopoulos, A.; Zervas, K.; Dimopoulos, M. A. (2014)Solitary plasmacytoma (SP) is a rare plasma cell dyscrasia characterized by the presence of bone or extramedullary plasma cell tumors. The treatment of choice is local radiotherapy (R/T) +/- surgical excision. The role of ... -
Docetaxel and Intermittent Erlotinib in Patients with Metastatic Non-small Cell Lung Cancer; A Phase II Study From The Hellenic Cooperative Oncology Group
Karavasilis, V.; Kosmidis, P.; Syrigos, K. N.; Mavropoulou, P.; Dimopoulos, M. A.; Kotoula, V.; Pectasides, D.; Boukovinas, I.; Klouvas, G.; Kalogera-Fountzila, A.; Papandreou, C. N.; Fountzilas, G.; Briasoulis, E. (2014)Aim: To determine the more effective dosing sequence of intermittent erlotinib and docetaxel for treating chemotherapy-naive patients with advanced Non-Small Cell Lung Cancer (NSCLC). Patients and Methods: Patients were ... -
Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial
Fountzilas, G.; Dafni, U.; Papadimitriou, C.; Timotheadou, E.; Gogas, H.; Eleftheraki, A. G.; Xanthakis, I.; Christodoulou, C.; Koutras, A.; Papandreou, C. N.; Papakostas, P.; Miliaras, S.; Markopoulos, C.; Dimitrakakis, C.; Korantzopoulos, P.; Karanikiotis, C.; Bafaloukos, D.; Kosmidis, P.; Samantas, E.; Varthalitis, I.; Pavlidis, N.; Pectasides, D.; Dimopoulos, M. A. (2014)Background: Dose-dense sequential chemotherapy including anthracyclines and taxanes has been established in the adjuvant setting of high-risk operable breast cancer. However, the preferable taxane and optimal schedule of ... -
Immunoglobulin D myeloma: Clinical features and outcome in the era of novel agents
Zagouri, F.; Kastritis, E.; Symeonidis, A. S.; Giannakoulas, N.; Katodritou, E.; Delimpasi, S.; Repousis, P.; Terpos, E.; Dimopoulos, M. A. (2014)Objectives: Immunoglobulin D (IgD) multiple myeloma is an uncommon variant of the disease probably associated with poorer prognosis. However, data on IgD myeloma patients treated in the novel agent era are lacking. Methods: ... -
Prospective, randomized phase III study comparing two intensified regimens (methotrexate/vinblastine/doxorubicin hydrochloride/cisplatin MVAC versus gemcitabine/cisplatin) in patients with inoperable or recurrent urothelial cancer
Bamias, A.; Karadimou, A.; Lampaki, S.; Aravantinos, G.; Xanthakis, I.; Papandreou, C.; Lainakis, G.; Zagouri, F.; Soupos, N.; Kostouros, E.; Samantas, E.; Hatzimouratidis, C.; Konstantinidis, C.; Deliveliotis, C.; Pectasides, D. G.; Fountzilas, G.; Dimopoulos, M. A.; Hellenic Cooperative Oncology, Grp (2011) -
Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group
Katodritou, E.; Terpos, E.; Kelaidi, C.; Kotsopoulou, M.; Delimpasi, S.; Kyrtsonis, M. C.; Symeonidis, A.; Giannakoulas, N.; Stefanoudaki, A.; Christoulas, D.; Chatziaggelidou, C.; Gastari, V.; Spyridis, N.; Verrou, E.; Konstantinidou, P.; Zervas, K.; Dimopoulos, M. A. (2014)Plasma cell leukemia (PCL) is a rare and aggressive plasma cell disorder, with poor outcome. Bortezomib-based regimens (BBR) are highly effective in myeloma, but there is limited information about their efficacy and safety ...